Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization

Endy Widya Putranto, Hitoshi Murata, Ken-ichi Yamamoto, Ken Kataoka, Hidenori Yamada, Junichiro Futami, Masakiyo Sakaguchi, Nam Ho Huh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The receptor for advanced glycation end products (RAGE) is a multi-ligand cell surface receptor and a member of the immunoglobulin superfamily. RAGE is involved in a wide range of inflammatory, degenerative and hyper-proliferative disorders which span over different organs by engaging diverse ligands, including advanced glycation end products, S100 family proteins, high-mobility group protein B1 (HMGB1) and amyloid β. We previously demonstrated that the cytoplasmic domain of RAGE is phosphorylated upon the binding of ligands, enabling the recruitment of two distinct pairs of adaptor proteins, Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) and myeloid differentiation protein 88 (MyD88). This engagement allows the activation of downstream effector molecules, and thereby mediates a wide variety of cellular processes, such as inflammatory responses, apoptotic cell death, migration and cell growth. Therefore, inhibition of the binding of TIRAP to RAGE may abrogate intracellular signaling from ligand-activated RAGE. In the present study, we developed inhibitor peptides for RAGE signaling (RAGE-I) by mimicking the phosphorylatable cytosolic domain of RAGE. RAGE-I was efficiently delivered into the cells by polyethylenimine (PEI) cationization. We demonstrated that RAGE-I specifically bound to TIRAP and abrogated the activation of Cdc42 induced by ligand-activated RAGE. Furthermore, we were able to reduce neuronal cell death induced by an excess amount of S100B and to inhibit the migration and invasion of glioma cells in vitro. Our results indicate that RAGE-I provides a powerful tool for therapeutics to block RAGE-mediated multiple signaling.

Original languageEnglish
Pages (from-to)938-944
Number of pages7
JournalInternational Journal of Molecular Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Polyethyleneimine
Peptides
Interleukin-1 Receptors
Ligands
Proteins
Advanced Glycosylation End Product-Specific Receptor
Cell Death
High Mobility Group Proteins
Advanced Glycosylation End Products
Peptide Receptors
S100 Proteins
Cell Surface Receptors
Cytoplasmic and Nuclear Receptors
Amyloid
Glioma
Cell Movement
Immunoglobulins

Keywords

  • Cationization
  • Cell death
  • Cell migration
  • Receptor for advanced glycation end products
  • S100B
  • Toll-interleukin 1 receptor domain-containing adaptor protein

ASJC Scopus subject areas

  • Genetics

Cite this

Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization. / Putranto, Endy Widya; Murata, Hitoshi; Yamamoto, Ken-ichi; Kataoka, Ken; Yamada, Hidenori; Futami, Junichiro; Sakaguchi, Masakiyo; Huh, Nam Ho.

In: International Journal of Molecular Medicine, Vol. 32, No. 4, 10.2013, p. 938-944.

Research output: Contribution to journalArticle

@article{41c3112eaa164dac9eff49cf45a9212f,
title = "Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization",
abstract = "The receptor for advanced glycation end products (RAGE) is a multi-ligand cell surface receptor and a member of the immunoglobulin superfamily. RAGE is involved in a wide range of inflammatory, degenerative and hyper-proliferative disorders which span over different organs by engaging diverse ligands, including advanced glycation end products, S100 family proteins, high-mobility group protein B1 (HMGB1) and amyloid β. We previously demonstrated that the cytoplasmic domain of RAGE is phosphorylated upon the binding of ligands, enabling the recruitment of two distinct pairs of adaptor proteins, Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) and myeloid differentiation protein 88 (MyD88). This engagement allows the activation of downstream effector molecules, and thereby mediates a wide variety of cellular processes, such as inflammatory responses, apoptotic cell death, migration and cell growth. Therefore, inhibition of the binding of TIRAP to RAGE may abrogate intracellular signaling from ligand-activated RAGE. In the present study, we developed inhibitor peptides for RAGE signaling (RAGE-I) by mimicking the phosphorylatable cytosolic domain of RAGE. RAGE-I was efficiently delivered into the cells by polyethylenimine (PEI) cationization. We demonstrated that RAGE-I specifically bound to TIRAP and abrogated the activation of Cdc42 induced by ligand-activated RAGE. Furthermore, we were able to reduce neuronal cell death induced by an excess amount of S100B and to inhibit the migration and invasion of glioma cells in vitro. Our results indicate that RAGE-I provides a powerful tool for therapeutics to block RAGE-mediated multiple signaling.",
keywords = "Cationization, Cell death, Cell migration, Receptor for advanced glycation end products, S100B, Toll-interleukin 1 receptor domain-containing adaptor protein",
author = "Putranto, {Endy Widya} and Hitoshi Murata and Ken-ichi Yamamoto and Ken Kataoka and Hidenori Yamada and Junichiro Futami and Masakiyo Sakaguchi and Huh, {Nam Ho}",
year = "2013",
month = "10",
doi = "10.3892/ijmm.2013.1467",
language = "English",
volume = "32",
pages = "938--944",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization

AU - Putranto, Endy Widya

AU - Murata, Hitoshi

AU - Yamamoto, Ken-ichi

AU - Kataoka, Ken

AU - Yamada, Hidenori

AU - Futami, Junichiro

AU - Sakaguchi, Masakiyo

AU - Huh, Nam Ho

PY - 2013/10

Y1 - 2013/10

N2 - The receptor for advanced glycation end products (RAGE) is a multi-ligand cell surface receptor and a member of the immunoglobulin superfamily. RAGE is involved in a wide range of inflammatory, degenerative and hyper-proliferative disorders which span over different organs by engaging diverse ligands, including advanced glycation end products, S100 family proteins, high-mobility group protein B1 (HMGB1) and amyloid β. We previously demonstrated that the cytoplasmic domain of RAGE is phosphorylated upon the binding of ligands, enabling the recruitment of two distinct pairs of adaptor proteins, Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) and myeloid differentiation protein 88 (MyD88). This engagement allows the activation of downstream effector molecules, and thereby mediates a wide variety of cellular processes, such as inflammatory responses, apoptotic cell death, migration and cell growth. Therefore, inhibition of the binding of TIRAP to RAGE may abrogate intracellular signaling from ligand-activated RAGE. In the present study, we developed inhibitor peptides for RAGE signaling (RAGE-I) by mimicking the phosphorylatable cytosolic domain of RAGE. RAGE-I was efficiently delivered into the cells by polyethylenimine (PEI) cationization. We demonstrated that RAGE-I specifically bound to TIRAP and abrogated the activation of Cdc42 induced by ligand-activated RAGE. Furthermore, we were able to reduce neuronal cell death induced by an excess amount of S100B and to inhibit the migration and invasion of glioma cells in vitro. Our results indicate that RAGE-I provides a powerful tool for therapeutics to block RAGE-mediated multiple signaling.

AB - The receptor for advanced glycation end products (RAGE) is a multi-ligand cell surface receptor and a member of the immunoglobulin superfamily. RAGE is involved in a wide range of inflammatory, degenerative and hyper-proliferative disorders which span over different organs by engaging diverse ligands, including advanced glycation end products, S100 family proteins, high-mobility group protein B1 (HMGB1) and amyloid β. We previously demonstrated that the cytoplasmic domain of RAGE is phosphorylated upon the binding of ligands, enabling the recruitment of two distinct pairs of adaptor proteins, Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) and myeloid differentiation protein 88 (MyD88). This engagement allows the activation of downstream effector molecules, and thereby mediates a wide variety of cellular processes, such as inflammatory responses, apoptotic cell death, migration and cell growth. Therefore, inhibition of the binding of TIRAP to RAGE may abrogate intracellular signaling from ligand-activated RAGE. In the present study, we developed inhibitor peptides for RAGE signaling (RAGE-I) by mimicking the phosphorylatable cytosolic domain of RAGE. RAGE-I was efficiently delivered into the cells by polyethylenimine (PEI) cationization. We demonstrated that RAGE-I specifically bound to TIRAP and abrogated the activation of Cdc42 induced by ligand-activated RAGE. Furthermore, we were able to reduce neuronal cell death induced by an excess amount of S100B and to inhibit the migration and invasion of glioma cells in vitro. Our results indicate that RAGE-I provides a powerful tool for therapeutics to block RAGE-mediated multiple signaling.

KW - Cationization

KW - Cell death

KW - Cell migration

KW - Receptor for advanced glycation end products

KW - S100B

KW - Toll-interleukin 1 receptor domain-containing adaptor protein

UR - http://www.scopus.com/inward/record.url?scp=84883423336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883423336&partnerID=8YFLogxK

U2 - 10.3892/ijmm.2013.1467

DO - 10.3892/ijmm.2013.1467

M3 - Article

VL - 32

SP - 938

EP - 944

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 4

ER -